Floatz logo

URACIL RIBOSIDE

HIV Infections

National Center for Complementary and Integrative Health (NCCIH)Small moleculePhase 2/3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
81/ 100

Competitive context

62 Active assets in the HIV Infections cohort.

Asset / SponsorPhaseRating
Raltegravir
Helsinki University Central Hospital
Phase 4A
Efavirenz
The Cleveland Clinic
Phase 4BBB
ZIDOVUDINE
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BBB
RITONAVIR
Giovanni Di Perri
Phase 4BBB
Abacavir
Germans Trias i Pujol Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

URACIL RIBOSIDE is also rated in:

lipodystrophyDormant
BB
Indicative ·
70 / 100
View asset →
metabolic diseaseDormant
B
Indicative ·
57 / 100
View asset →
nutritional deficiency diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →